Author: Du, Peng; Geng, Jie; Wang, Feng; Chen, Xiaobo; Huang, Zhiwei; Wang, Yuliang
Title: Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome Cord-id: jt0cs3ez Document date: 2021_1_21
ID: jt0cs3ez
Snippet: Cytokine release syndrome (CRS) may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19). As a major driver in triggering CRS in patients with COVID-19, interleukin-6 (IL-6) appears to be a promising target for therapeutics. The results of inhibiting both trans- and classical- signaling with marketed IL-6 inhibitors (tocilizumab, siltuximab and sarilumab) in severe COVID-19 patients are effective based on several small studies and case reports thus far. In this review
Document: Cytokine release syndrome (CRS) may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19). As a major driver in triggering CRS in patients with COVID-19, interleukin-6 (IL-6) appears to be a promising target for therapeutics. The results of inhibiting both trans- and classical- signaling with marketed IL-6 inhibitors (tocilizumab, siltuximab and sarilumab) in severe COVID-19 patients are effective based on several small studies and case reports thus far. In this review, we described the evidence of the IL-6 response in patients with COVID-19, clarified the pathogenesis of the role of IL-6-mediated CRS in severe COVID-19, and highlighted the rationale for the use of anti-IL-6 agents and key information regarding the potential features of these IL-6 inhibitors in COVID-19 patients.
Search related documents:
Co phrase search for related documents- activator signal transducer and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- activator signal transducer and adaptive innate: 1, 2, 3, 4
- activator signal transducer and adhesion molecule: 1, 2, 3, 4
- activator signal transducer and lung infection: 1, 2, 3
- activator signal transducer and lung inflammation: 1, 2, 3, 4, 5, 6, 7
- activator signal transducer and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- activator signal transducer and macrophage activation: 1, 2
- activity block and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- activity block and adaptive innate: 1
- activity block and macrophage activation: 1
- acute phase and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute phase and adhesion molecule: 1, 2
- acute phase and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- acute phase and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute phase and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
- acute phase and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute phase and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute phase and macrophage monocyte: 1, 2, 3
- acute phase response and adaptive innate: 1, 2
Co phrase search for related documents, hyperlinks ordered by date